2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidence
2023
HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis
Mezzacappa C, Mahmud N, Serper M, John B, Taddei T, Kaplan D. HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis. Hepatology Communications 2023, 7: e0344. PMID: 38055642, PMCID: PMC10984661, DOI: 10.1097/hc9.0000000000000344.Peer-Reviewed Original ResearchRate of HCCBlood glucose controlBG controlIncident HCCGlucose controlCox proportional hazards regressionEtiology of cirrhosisProportional hazards regressionUnited States veteransHemoglobin A1c measurementsCirrhosis careHgb A1cHCC ratesHazards regressionNational cohortHCC riskA1c measurementStates veteransCirrhosisHigh riskDiabetesSustained controlHCCControl stateCohort
2022
Systems approach to enhance Lynch syndrome diagnosis through tumour testing
Singh V, Mezzacappa C, Gershkovich P, Di Giovanna J, Ganzak A, Gibson J, Sinard J, Xicola RM, Llor X. Systems approach to enhance Lynch syndrome diagnosis through tumour testing. Journal Of Medical Genetics 2022, 60: 533-539. PMID: 36115663, PMCID: PMC10020126, DOI: 10.1136/jmg-2022-108770.Peer-Reviewed Original ResearchConceptsOriginal cohortColorectal adenocarcinomaLynch syndromeTumor testingGenetic testingPercentage of patientsProportion of patientsLynch syndrome diagnosisCG evaluationCancer genetic testingRace/ethnicityCRC testingCohort studyMMR immunohistochemistryLS diagnosisNew diagnosisMMR lossAcademic centersPatientsSyndrome diagnosisCohortCase identificationMethylation testingReferral differencesReferral mechanisms